Tekmira Pharmaceuticals and Pfizer have launched a new research collaboration to evaluate Tekmira’s stable nucleic acid-lipid particle (SNALP) technology’s ability to deliver small interfering RNA (siRNA) molecules provided by Pfizer. Tekmira will be responsible for preparing the SNALP formulations and Pfizer will evaluate the formulations in preclinical models. Financial terms of the collaboration were not disclosed. Dr. Mark J. Murray, Tekmira’s president and chief executi...